# Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy

**Authors:** Marta Zaninello, Konstantinos Palikaras, Deborah Naon, Keiko Iwata, Stephanie Herkenne, Ruben Quintana-Cabrera, Martina Semenzato, Francesca Grespi, Fred N. Ross-Cisneros, Valerio Carelli, Alfredo A. Sadun, Nektarios Tavernarakis, Luca Scorrano

PMC · DOI: 10.1038/s41467-020-17821-1 · 2020-08-12

## TL;DR

This study shows that blocking autophagy can prevent vision loss in a mouse model of a genetic eye disorder caused by OPA1 mutations.

## Contribution

The study identifies AMPK-induced autophagy as a novel therapeutic target for autosomal dominant optic atrophy.

## Key findings

- AMPK and ULK1 accumulate at axonal hillocks in retinal ganglion cells with mutated Opa1, triggering autophagy.
- Genetic inhibition of AMPK and autophagy restores mitochondrial content in axons affected by Opa1 mutations.
- Depletion of Atg7 in mice reverses visual defects caused by Opa1 deficiency, highlighting autophagy as a targetable pathway.

## Abstract

In autosomal dominant optic atrophy (ADOA), caused by mutations in the mitochondrial cristae biogenesis and fusion protein optic atrophy 1 (Opa1), retinal ganglion cell (RGC) dysfunction and visual loss occur by unknown mechanisms. Here, we show a role for autophagy in ADOA pathogenesis. In RGCs expressing mutated Opa1, active 5’ AMP-activated protein kinase (AMPK) and its autophagy effector ULK1 accumulate at axonal hillocks. This AMPK activation triggers localized hillock autophagosome accumulation and mitophagy, ultimately resulting in reduced axonal mitochondrial content that is restored by genetic inhibition of AMPK and autophagy. In C. elegans, deletion of AMPK or of key autophagy and mitophagy genes normalizes the axonal mitochondrial content that is reduced upon mitochondrial dysfunction. In conditional, RGC specific Opa1-deficient mice, depletion of the essential autophagy gene Atg7 normalizes the excess autophagy and corrects the visual defects caused by Opa1 ablation. Thus, our data identify AMPK and autophagy as targetable components of ADOA pathogenesis.

Autosomal dominant optic atrophy is caused by mutations in the mitochondrial fusion protein OPA1. Here, the authors show that AMPK-induced autophagy depletes mitochondria in axons of retinal ganglion cells and that autophagic inhibition reverses vision loss in a mouse model.

## Linked entities

- **Genes:** OPA1 (OPA1 mitochondrial dynamin like GTPase) [NCBI Gene 4976], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], ULK1 (unc-51 like autophagy activating kinase 1) [NCBI Gene 8408], ATG7 (autophagy related 7) [NCBI Gene 10533]
- **Proteins:** ULK1 (unc-51 like autophagy activating kinase 1)
- **Diseases:** autosomal dominant optic atrophy (MONDO:0020250)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** OPA1 (OPA1 mitochondrial dynamin like GTPase) [NCBI Gene 4976] {aka BERHS, MGM1, MTDPS14, MTDPS14A, MTDPS14B, NPG}, Map1lc3b (microtubule-associated protein 1 light chain 3 beta) [NCBI Gene 67443] {aka 1010001C15Rik, Atg8, LC3b, MAP1A/MAP1B, Map1lc3}, Nup62 (nucleoporin 62) [NCBI Gene 18226] {aka D7Ertd649e, Nupc1, p62}, Fis1 (fission, mitochondrial 1) [NCBI Gene 66437] {aka 2010003O14Rik, Ttc11}, Slc11a2 (solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2) [NCBI Gene 18174] {aka DCT1, DMT1, Nramp2, mk, van}, Pou4f1 (POU domain, class 4, transcription factor 1) [NCBI Gene 18996] {aka Brn-3, Brn-3.0, Brn3, Brn3.0, Brn3a, E130119J07Rik}, rol-6 (Cuticle collagen rol-6) [NCBI Gene 174397], ATG7 (autophagy related 7) [NCBI Gene 10533] {aka APG7-LIKE, APG7L, GSA7, SCAR31}, Grik4 (glutamate receptor, ionotropic, kainate 4) [NCBI Gene 110637] {aka 6330551K01Rik, GluK4, GluRgamma1, KA-1, KA1}, Thy1 (thymus cell antigen 1, theta) [NCBI Gene 21838] {aka CD90, T25, Thy-1, Thy-1.2, Thy1.1, Thy1.2}, Ulk1 (unc-51 like kinase 1) [NCBI Gene 22241] {aka Unc51.1, mKIAA0722}, Mfn2 (mitofusin 2) [NCBI Gene 170731] {aka D630023P19Rik, Fzo}, Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Opa1 (OPA1, mitochondrial dynamin like GTPase) [NCBI Gene 74143] {aka 1200011N24Rik, lilr3, mKIAA0567}, aak-2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) [NCBI Gene 181727], lgg-2 (Protein lgg;Protein lgg-2) [NCBI Gene 177989], Prss28 (serine protease 28) [NCBI Gene 114661] {aka Isp1, mIsp-1}, Dnm1l (dynamin 1-like) [NCBI Gene 74006] {aka 6330417M19Rik, Dlp1, Dnmlp1, Drp1, python}, Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, Fabp6 (fatty acid binding protein 6) [NCBI Gene 16204] {aka GT, I-15P, I-BABP, ILBP, ILBP3, Illbp}, Tomm20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 67952] {aka 1810060K07Rik, Gm19268, MAS20, MOM19, TOM20, mKIAA0016}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, Atg7 (autophagy related 7) [NCBI Gene 74244] {aka 1810013K23Rik, Agp7, Apg7l, Atg7l, Gm21553}, Unc119 (unc-119 lipid binding chaperone) [NCBI Gene 22248] {aka D11Bhm52, HRG4, MRG4, Rg4, Rtg4, Unc119h}, unc-119 (Protein unc-119) [NCBI Gene 176519], Bnip3l (BCL2/adenovirus E1B interacting protein 3-like) [NCBI Gene 12177] {aka D14Ertd719e, Nip3L, Nix}, Mff (mitochondrial fission factor) [NCBI Gene 75734] {aka 5230400G24Rik}, aak-1 (5'-AMP-activated protein kinase catalytic subunit alpha-1) [NCBI Gene 176230]
- **Diseases:** axonal and dendritic dysfunction (MESH:D007635), RGC (MESH:D012173), mitochondrial fragmentation (MESH:D012892), loss of vision (MESH:D014786), mitochondrial defect (MESH:C565376), Genetic diseases (MESH:D030342), impaired mitochondrial function (MESH:D028361), Parkinson's disease (MESH:D010300), blind (MESH:D001766), ADOA (MESH:D029241), neurodegeneration (MESH:D019636), retinal ganglion cell (RGC) dysfunction (MESH:D012164), Charcot-Marie-Tooth 2a (MESH:C537988), Alzheimer's disease (MESH:D000544), LHON (MESH:D029242), amyotrophic lateral sclerosis (MESH:D000690), neurological disorders (MESH:D009461), neurological diseases (MESH:D020271),  (MESH:D004195)
- **Chemicals:** GABA (MESH:D005680), DAPI (MESH:C007293), TRITC (MESH:C009434), Bafilomycin A (MESH:C057620), Rapamycin (MESH:D020123), FITC (MESH:D016650), paraformaldehyde (MESH:C003043), l-glutamine (MESH:D005973), poly-l-ornithine (MESH:C008973), agarose (MESH:D012685), sucrose (MESH:D013395), AMP (MESH:D000249), CO2 (MESH:D002245), levamisole (MESH:D007978), SYBR Green (MESH:C098022), paraquat (MESH:D010269), O (MESH:D010100), CCCP (MESH:D002258), Triton-X-100 (MESH:D017830), formaldehyde (MESH:D005557), N-2 (MESH:D009584), 4',6-diamidin-2-phenylindole (-), ATP (MESH:D000255), tetramethylrhodamine (MESH:C005358), PBS (MESH:D007854)
- **Species:** C. elegans [taxon 328850], Homo sapiens (human, species) [taxon 9606], Caenorhabditis elegans (species) [taxon 6239], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C with 3, G93A, Q297V
- **Cell lines:** adIs2122[plgg — Homo sapiens (Human), Transformed cell line (CVCL_K883), DA2123 — Homo sapiens (Human), Huntington's disease, Finite cell line (CVCL_1H43), -119TOMM-20::Rosella — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TT27), IR1797 — Homo sapiens (Human), Transformed cell line (CVCL_1D28), C57Bl/6J — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0192), N2 — Mus musculus (Mouse), Mouse neuroblastoma, Cancer cell line (CVCL_0470), IR1864 — Homo sapiens (Human), Finite cell line (CVCL_7342)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7423926/full.md

---
Source: https://tomesphere.com/paper/PMC7423926